Kazia Therapeutics (KZIA) Receivables (2009 - 2025)

Kazia Therapeutics has reported Receivables for 15 years, with the latest figure at $409303.3 in Q4 2025.

• For the quarter ending Q4 2025, Receivables rose 551.07% year-over-year to $409303.3; the trailing twelve-month figure through Dec 2025 stood at $409303.3 (up 551.07% YoY), and the FY2025 full-year result was $120487.9, down 95.46% from the prior year.
• Receivables for Q4 2025 stood at $409303.3, up from $120487.9 in the prior quarter.
• The five-year high for Receivables was $2.7 million in Q2 2023, with the low at $55154.8 in Q4 2021.
• Historically, Receivables has averaged $1.1 million across 5 years, with a median of $266256.1 in 2021.
• Annual changes were most pronounced in 2022 — Receivables soared 4325.72% — and 2024, when it tumbled 97.45%.
• Kazia Therapeutics' Receivables stood at $55154.8 in 2021, then surged by 4325.72% to $2.4 million in 2022, then gained by 0.88% to $2.5 million in 2023, then plunged by 97.45% to $62866.2 in 2024, then surged by 551.07% to $409303.3 in 2025.
• The last three Receivables figures came in at $409303.3 (Q4 2025), $120487.9 (Q2 2025), and $62866.2 (Q4 2024), per Business Quant data.